Semaglutide Improves Clinical and Metabolic Outcomes in Hidradenitis Suppurativa with Obesity: Study

Spain: A new study has found that treatment with Semaglutide in patients with Hidradenitis Suppurativa and obesity led to improvements in weight, body composition, metabolic and inflammatory markers, as well as dermatologic and psychological status. Further, several benefits persisted even after adjusting for weight loss.
- After six months of treatment with Semaglutide, participants showed a substantial reduction in body weight, with an average loss of about 21.4 kg.
- Significant improvements were also observed in body mass index, waist circumference, blood pressure, and levels of preperitoneal and subcutaneous fat.
- Disease severity of Hidradenitis suppurativa decreased in all participants, as reflected by improvements in the Hurley staging system.
- Patient-reported quality of life improved notably, with a marked reduction in Dermatology Life Quality Index (DLQI) scores.
- Pain intensity declined significantly during the study period, based on visual analogue scale (VAS) scores.
- Participants experienced a considerable reduction in depressive symptoms, indicated by improved scores on the Beck Depression Inventory (BDI).
- Favorable changes were also seen in metabolic and inflammatory laboratory markers, suggesting broader health benefits beyond weight reduction.
- Even after adjusting for weight loss, several improvements remained statistically significant, including better dermatology-related quality of life, reduced pain, lower depressive symptoms, reduced disease severity, and improved levels of vitamin D, C-reactive protein (CRP), and cortisol.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
